Patents Assigned to Pfizer Inc.
  • Combinations for Treatment of NAFLD/NASH and Related Diseases
    Publication number: 20230218616
    Abstract: A method for treating fatty liver disease and related diseases or disorders with a therapeutically effective amount of a composition comprising from about 25 mg to about 1200 mg of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or a pharmaceutically acceptable salt thereof, and from about 5 mg to about 40 mg of 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4?-piperidine]-1?-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 22, 2021
    Publication date: July 13, 2023
    Applicant: Pfizer Inc.
    Inventors: Neeta Balkrishan Amin, Arthur James Bergman, Roberto Arnaldo Calle, William Paul Esler, Albert Myung Kim, Jeffrey Allen Pfefferkorn, Patrick Robert Verhoest
  • PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES
    Publication number: 20230219963
    Abstract: Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.
    Type: Application
    Filed: May 25, 2021
    Publication date: July 13, 2023
    Applicant: Pfizer Inc.
    Inventors: Martin Eugene Dowty, Bimal Kumar Malhotra, Ivan Jordan Samardjiev, Brian Matthew Samas, Joseph Walter Strohbach
  • Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof
    Patent number: 11697678
    Abstract: The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides. The invention also features methods of using sFGFR3 polypeptides to treat skeletal growth regardation disorders, such as achondroplasia.
    Type: Grant
    Filed: April 20, 2021
    Date of Patent: July 11, 2023
    Assignees: Pfizer Inc., INSERM (Institut National de la Santé et de la Recherche Médicale), Université Côte d'Azur
    Inventors: Elvire Gouze, Stéphanie Garcia
  • 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors
    Patent number: 11691973
    Abstract: The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof. The invention further relates to solid forms of 8-((2-fluoro-4-(methylthio)phenyl)amino)-2-(2-hydroxyethoxy)-7-methyl-3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-dione.
    Type: Grant
    Filed: December 1, 2022
    Date of Patent: July 4, 2023
    Assignee: Pfizer Inc.
    Inventors: Shelley Allen, Patrick Michael Doerner Barbour, James Francis Blake, Sydney Taylor Blanche, Mark Laurence Boys, Wesley Dewitt Clark, Connor James Cowdrey, Joshua Ryan Dahlke, Alex Andrew Kellum, Ellen Margaret Knapp, David Austin Moreno, Jacob Matthew O'Leary, Li Ren, Faith Elizabeth Witkos, Jennifer Lynn Fulton
  • SOLID STATE FORMS OF (S)-2-(((S)-6,8-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)AMINO)-N-(1-(2-METHYL-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE AND USES THEREOF
    Publication number: 20230202987
    Abstract: The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
    Type: Application
    Filed: February 17, 2023
    Publication date: June 29, 2023
    Applicant: Pfizer Inc.
    Inventors: Elaine GREER, Stephen ANDERSON, Mark MALONEY, Shu YU, Ekaterina ALBERT, Emily RIGSBEE
  • TREATMENT OF TYPE 2 DIABETES OR OBESITY OR OVERWEIGHT WITH 2-[(4-{6-[(4-CYANO-2-FLUOROBENZYL)OXY]PYRIDIN-2-YL}PIPERIDIN-1-YL)METHYL]-1-[(2S)-OXETAN-2-YLMETHYL]-1H-BENZIMIDAZOLE-6-CARBOXYLIC ACID OR A PHARMACEUTICALLY SALT THEREOF
    Publication number: 20230201185
    Abstract: The invention provides a method for treating T2DM, obesity or overweight or for weight management control by administering to an mammal (e.g. a human) in need thereof a pharmaceutical composition twice daily in an oral dosage form, wherein the pharmaceutical composition contains 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-5 [(2S)-oxetan-2-ylmethyl]-1H-benzimidazole carboxylic acid, or a pharmaceutically salt thereof [such as its tris salt]. Moreover, the invention provides oral compositions/formulations for the methods of treatment described herein.
    Type: Application
    Filed: March 24, 2021
    Publication date: June 29, 2023
    Applicant: Pfizer Inc.
    Inventors: Kai Teck Lee, Sweta Manthena, Aditi Rao Saxena
  • Azalactam compounds as HPK1 inhibitors
    Patent number: 11684616
    Abstract: This invention relates to compounds of general Formula I and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: June 27, 2023
    Assignee: PFIZER INC.
    Inventors: Joyann Barber, Sujin Cho-Schultz, Matthew L. Del Bel, Rebecca Anne Gallego, Mingying He, Mehran Jalaie, Robert Steven Kania, Michele Ann McTigue, Sajiv Krishnan Nair, Anne-Marie Dechert Schmitt, Jamison Bryce Tuttle, Dahui Zhou, Ru Zhou
  • METHODS, THERAPIES AND USES FOR TREATING CANCER
    Publication number: 20230192878
    Abstract: The present disclosure describes single agent and combination therapies and uses for the treatment of cancer and/or cancer-associated diseases. The single agent and combinations therapies include a BCMA antibody.
    Type: Application
    Filed: May 13, 2021
    Publication date: June 22, 2023
    Applicant: PFIZER INC.
    Inventors: Nathalie Annie BARDY BOUXIN, Eloisa Virginia BARRY, John Andrew BLAKE-HASKINS, Geoffrey Wing-Lynn CHAN, Jeffrey CHOU, Mohamed A ELMELIEGY, Heike Iris KRUPKA, Kai Hsin LIAO, Erik Rene VANDENDRIES, Andrea VIQUEIRA, Paul Stephen WISSEL, Anne YVER
  • ANTIBODIES HAVING CONDITIONAL AFFINITY AND METHODS OF USE THEREOF
    Publication number: 20230192839
    Abstract: Provided herein are antibodies with conditional affinity for an antigen. The affinity of an antibody with conditional affinity for an antigen may be altered by a small molecule agent. Antibodies with conditional affinity may be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.
    Type: Application
    Filed: March 29, 2018
    Publication date: June 22, 2023
    Applicant: PFIZER INC.
    Inventors: Bijan Andre BOLDAJIPOUR, Javier Fernando CHAPARRO RIGGERS, Xiaodi DENG, Kevin Charles LINDQUIST, Spencer PARK, Edward Derrick PASCUA, Thomas John VAN BLARCOM
  • compositions and methods thereof
    Patent number: 11680087
    Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 ?g/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 ?g/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: June 20, 2023
    Assignee: Pfizer Inc.
    Inventors: Annaliesa Sybil Anderson, Rasappa Gounder Arumugham, John Erwin Farley, Leah Diane Fletcher, Shannon Lea Harris, Kathrin Ute Jansen, Thomas Richard Jones, Lakshmi Khandke, Bounthon Loun, John Lance Perez, Gary Warren Zlotnick
  • Universal antibody libraries
    Patent number: 11674240
    Abstract: Universal antibody libraries are described which are synthetic and derived from expressed human antibody sequences selected accordingly to certain criteria, for example, that the sequences are derived from naturally-occurring antibodies expressed in response to a certain antigen class (e.g., small molecule, polysaccharide, peptide, or protein) and having CDR regions engineered for optimal diversity. Methods for making and screening such libraries for isolating therapeutics suitable for treating disease are also disclosed.
    Type: Grant
    Filed: July 6, 2005
    Date of Patent: June 13, 2023
    Assignee: Pfizer Inc.
    Inventors: Roberto Crea, Arvind Rajpal, Guido Cappuccilli, Randy Shen, Toshihiko Takeuchi
  • DLL3 targeting chimeric antigen receptors and binding agents
    Patent number: 11673953
    Abstract: Provided herein are DLL3 binding agents and chimeric antigen receptors (CARs) comprising a DLL3 binding molecule that specifically binds to DLL3; and immune cells comprising these DLL3-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using DLL3-specific CARs, and immune cells comprising DLL3-specific CARs.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: June 13, 2023
    Assignees: ALLOGENE THERAPEUTICS, INC., PFIZER INC.
    Inventors: Yi Zhang, Thomas John Van Blarcom, Siler Panowski, Silvia K. Tacheva-Grigorova, Barbra Johnson Sasu
  • N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors
    Patent number: 11673890
    Abstract: The invention provides a compound of Formula (1) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Grant
    Filed: September 28, 2020
    Date of Patent: June 13, 2023
    Assignee: Pfizer Inc.
    Inventors: Mary Theresa Didiuk, Robert Lee Dow, David Andrew Griffith
  • METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR
    Publication number: 20230174532
    Abstract: Described herein are methods of treating MC4R-related conditions, diseases, or disorders by administering compounds of Formula I: or their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein. Such conditions, diseases, or disorders include cachexia, anorexia, or anorexia nervosa.
    Type: Application
    Filed: January 31, 2023
    Publication date: June 8, 2023
    Applicant: Pfizer Inc.
    Inventors: Christopher Ryan BUTLER, Michelle Renee GARNSEY, Kevin Alexander OGILVIE, Jana POLIVKOVA, Matthew Forrest SAMMONS, Aaron Christopher SMITH, Qingyi Yang
  • COMPOSITIONS COMPRISING THREE OSPA FUSION PROTEINS FOR MEDICAL USE
    Publication number: 20230173051
    Abstract: The present invention relates to a composition comprising the OspA fusion protein of SEQ ID NO: 1 (LipSID1-S2D1), the OspA fusion protein of SEQ ID NO: 2 (Lip-S4D1-SShybD1) and the OspA fusion protein of SEQ ID NO: 3 (Lip-S5D1-S6D1) for use in a vaccine or for use in a method for eliciting an immune response in a human against Lyme disease.
    Type: Application
    Filed: April 9, 2021
    Publication date: June 8, 2023
    Applicants: Valneva Austria GmbH, Pfizer Inc.
    Inventors: Nicole Bézay, Romana Hochreiter, Urban Lundberb, Steven Russell Bailey, Annaliesa Sybil Anderson, Kathrin Ute Jansen, Daniel Alfred Scott
  • BCKDK INHIBITORS AND/OR DEGRADERS
    Publication number: 20230167080
    Abstract: Described herein are compounds of Formula I, wherein the variables are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, diabetes, kidney disease, NASH and heart failure.
    Type: Application
    Filed: November 30, 2022
    Publication date: June 1, 2023
    Applicant: Pfizer Inc.
    Inventors: Leanne Marie BUZON, Kimberly O'Keefe CAMERON, Kevin Francis DEBOYACE, Kevin James FILIPSKI, David Andrew GRIFFITH, Bethany Lyn KORMOS, Shenping LIU, Luis Angel MARTINEZ ALSINA, Matthew Richard REESE, Rachel Jane ROTH FLACH, Yuan ZHANG
  • MODIFIED NUCLEIC ACIDS ENCODING ASPARTOACYLASE (ASPA) AND VECTOR FOR GENE THERAPY
    Publication number: 20230165977
    Abstract: The present disclosure relates to recombinant nucleic acids and gene therapy vectors comprising a modified nucleic acid encoding aspartoacylase (ASPA), and variants thereof, for use in the treatment of diseases and disorders associated with a deficiency or dysfunction of ASPA, and in particular, Canavan disease.
    Type: Application
    Filed: April 22, 2021
    Publication date: June 1, 2023
    Applicant: Pfizer Inc.
    Inventors: Paola Leone, Jeremy Francis, Basel T. Assaf, Shoh Asano, Kathrine Hales, Allison P. Berg
  • SOLID STATE FORMS OF (S)-2-(((S)-6,8-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)AMINO)-N-(1-(2-METHYL-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE AND USES THEREOF
    Publication number: 20230167069
    Abstract: The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
    Type: Application
    Filed: January 27, 2023
    Publication date: June 1, 2023
    Applicant: Pfizer Inc.
    Inventors: Elaine GREER, Stephen ANDERSON, Mark MALONEY, Shu YU, Ekaterina ALBERT, Emily RIGSBEE
  • Benzimidazole derivative compounds and uses thereof
    Patent number: 11661419
    Abstract: The invention relates to benzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: May 30, 2023
    Assignee: Pfizer Inc.
    Inventors: Scott William Bagley, Agustin Casimiro-Garcia, Xiayun Cheng, Jennifer Elizabeth Davoren, Rajiah Aldrin Denny, Brian Stephen Gerstenberger, Frank Eldridge Lovering, Mihir Dineshkumar Parikh, Joseph Walter Strohbach, John Isidro Trujillo
  • Purification of antibody drug conjugates using a sodium phosphate gradient
    Patent number: 11661438
    Abstract: Methods of removing high molecular weight species, in particular aggregates, from antibody drug conjugate preparations, by contacting preparations of the antibody drug conjugate reaction mixture with a hydroxyapatite resin and selectively eluting the ADC from the resin using a gradient comprising sodium phosphate.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: May 30, 2023
    Assignee: Pfizer, Inc.
    Inventors: Durgesh V. Nadkarni, Jeffry R. Borgmeyer, He Meng, Qingping Jiang